Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2018 financial results before the Nasdaq Global Market open on Thursday, March 14, 2019.
| Conference Call Dial-In Information: | ||||
| Participant Toll-Free Dial-In Number: | (877) 388-2733 | |||
| Participant International Dial-In Number: | (541) 797-2984 | |||
| Pass Code: | 3873249 | |||
Please specify to the operator that you would like to join the “Catabasis Fourth Quarter and Full Year 2018 Results Call.”
Interested parties may access a live audio webcast of the conference call via the investor section of the Catabasis website, www.catabasis.com. Please connect to the Catabasis website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190228005165/en/
Contacts
Investor and Media Contact
Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com
Source: Catabasis Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190228005165/en
